Expression of hMLH1 and hMSH2 in Patients with Sporadic Colorectal Cancer

余国庆,赫永金,许迪锋,朱玲华
DOI: https://doi.org/10.11735/j.issn.1671-170X.2014.07.B008
2014-01-01
Abstract:[Purpose] To investigate the expression of human mutL homolog 1(hMLH1) and human mutS homolog 2(hMSH2) in sporadic colorectal cancer. [Methods] Expression of hMLH1 and hMSH2 in 127 cases with colorectal cancer without radiotherapy or chemotherapy before operation and 20 cases of non-cancer patients endoscopically proved was detected immunohistochemically. [Results] The loss rate of hMSH2 expression in colorectal cancer tissue was higher than that in control tissue(65.4% vs 20.0%,χ2=14.714,P0.001). The loss rate of hMSH2 expression increased with T staging(χ2=8.233,P=0.041),and was correlated with N stage(χ2=20.235,P0.001). The loss rate of hMSH2 expression in patients with lymph node metastases was 87.1%(27/31),higher than that in patients without lymph node metastases(54.2%)(χ2=9.250,P=0.002).The loss rate of hMLH1 expression in colorectal cancer tissue was 74.0%,and was correlated with T stage(χ2=29.115,P0.001),N stage(χ2=9.807,P=0.006),M stage(χ2=7.363,P=0.007).[Conclusion]There is loss expression of HMLH1 and hMSH2 in colorectal cancer,and immunohistochemistry can find mutation of mismatch repair genes easily and accurately,which can provide a reference for late treatment and prognostic evaluation.
What problem does this paper attempt to address?